SAN FRANCISCO -- Radiation therapy (RT) after surgery for high-risk muscle-invasive bladder cancer significantly reduced the rate of local recurrence and improved survival, according to a randomized ...

Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...

What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...

Zusduri is expected to be available on or around July 1, 2025. The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade ...

Treatment with UGN-102 in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer demonstrated beneficial responses. Patients with recurrent low-grade intermediate-risk ...

Having high levels of the biomarker carbohydrate antigen 19-9 before surgery is associated with bladder cancer recurrence among patients who undergo radical cystectomy. In patients with bladder cancer ...

UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) UroGen Pharma Ltd ...

James Stewart puts on his rollerblades to get ready to do the trail in Rabb Park on his day off. He continues to be able to ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

18-month DOR of 80.6% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%) Data unveiled during a Podium Presentation at the American ...

Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone WILMINGTON, Del.-- ...